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ABSTRACT
Objectives: Detection of mutations associated to nucleos(t)ide analogs and hepatitis B virus (HBV) 
genotyping are essential for monitoring treatment of HBV infection. We developed a multiplex poly-
merase chain reaction-ligase detection reaction (PCR-LDR) assay for the rapid detection of HBV geno-
types and mutations associated with lamivudine, adefovir, and telbivudine resistance in HBV-infected 
patients. Methods: HBV templates were amplified by PCR, followed by LDR and electrophoresis on a 
sequencer. The assay was evaluated using plasmids that contained wild-type or mutant HBV se-
quences and 216 clinical samples. Results: The PCR-LDR assay and sequencing gave comparable 
results for 158 of the 216 samples (73.1%) with respect to mutation detection and genotyping. Com-
plete agreement between the two methods was observed for all the samples (100%) at codon 180 and 
codon 204. Concordant results were observed for 99.4% of the 158 samples at codon 181 and 98.7% 
at codon 236. The genotyping results were completely concordant between the PCR-LDR assay 
and sequencing. The PCR-LDR assay could detect a proportion of 1% mutant plasmid in a back-
ground of wild-type plasmid. Conclusion: The PCR-LDR assay is sensitive and specific for detection 
of HBV genotypes and drug resistance mutations, and could be helpful for decision making in the 
treatment of HBV infection.
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INTRODUCTION
Hepatitis B virus (HBV) infection is a major 
health problem worldwide. Antiviral thera-
pies with interferon, pegylated interferon, or 
nucleos(t)ide analogs are widely used to treat 
HBV infection. Given that these therapies 
cannot eradicate HBV infection, the focus of 
the treatment is to prolong the suppression 
of viral replication, prevent complications of 
infection, and establish immune control by 
the host over the virus.1 The effectiveness of 
interferon and pegylated interferon therapy 
depends on the specific genotype of HBV with 
which the patient is infected.2,3 In addition, the 
presence of mutations that confer drug resist-
ance often lead to the failure of treatment with 
nucleos(t)ide analogs.4 HBV has been classi-
fied into eight major genotypes (designated 
from A to H), on the basis of an intergroup 
divergence of 8% or more in the full-length nu-
cleotide sequence, and most of the genotypes 
show a distinct geographic distribution.5,6 There 
is evidence that genotypes A and B are associ-
ated with higher rates of hepatitis B e antigen 
(HBeAg) seroconversion than genotypes C and 
D during treatment with interferon or pegylated 
interferon.2,3,7,8 Genotyping of HBV is essential 
to detect patients who are highly likely to re-
spond to interferon or pegylated interferon.9,10
The primary mutation that confers resist-
ance to the nucleoside analog lamivudine is 
rtM204V/I, which is located in the tyrosine-
methionine-aspartate-aspartate (YMDD) motif 
of the HBV DNA polymerase, and is often 
accompanied by the mutation rtL180M. HBV 
that carries rtM204I or rtM204V + rtL180M is 
also resistant to telbivudine in cell culture.4 The 
primary mutations that confer resistance to 
the nucleotide analog adefovir (ADV) are 
rtN236T and/or rtA181T/V.4 Resistance to 
entecavir may be caused by a two-hit mech-
anism with initial selection of M204V/I 
mutation followed by the occurrence of 
rtT184S/A/I/L/F/G, rtS202G/I, or rtM250V.11 
The frequency of mutations for lamivudine 
resistance increases with the duration of lami-
vudine treatment, and reaches cumulative rates 
of 15%, 38%, 56%, and 67% in years 1, 2, 3, and 
4 of treatment, respectively.12-15 In chronic hep-Este é um artigo Open Access sob
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atitis B patients who have not been exposed to nucleoside treat-
ment previously, adefovir resistance mutations only emerge in 
the second year of treatment, and the frequency of these muta-
tions reaches cumulative rates of 3%, 6%, 18%, and 29% at the 
end of 2, 3, 4, and 5 years of therapy, respectively.16,17 Adefovir 
resistance mutations are much more common in patients who 
have previously received lamivudine therapy.18 
HBV infection is a heavy health burden in China. Nation-
al surveys found that the prevalence of HBV was 9.8% in 1992 
and 7.2% in 2006 among the population aged 1–59 years. Due 
to the National Hepatitis B Vaccination to Infant Program, the 
prevalence of HBV has been dramatically reduced.19 However, 
because this program was only started in 1992, the prevalence 
rate of HBV is still high in those aged above 18 years, and the 
treatment of HBV-infected patients is still an important issue 
in China. The State Food and Drug Administration of China 
has approved interferon, pegylated interferon, lamivudine, 
adefovir, telbivudine, and entecavir for the treatment of HBV 
infection. All these drugs are widely used in China to treat 
HBV-infected patients. HBV genotyping and the detection of 
mutations that confer drug resistance help the selection of an 
appropriate treatment strategy and monitoring of the treat-
ment. However, there are a limited number of methods that 
enable genotyping and mutation detection to be carried out 
simultaneously. Although nucleotide sequencing of PCR 
products is widely used for HBV genotyping and mutational 
analysis, the technique can only detect mutant virus when it 
comprises at least 25% of the total viral population.20 The re-
verse hybridization-based line-probe assay LiPA DR is more 
sensitive and can detect resistance mutations when the mu-
tant virus comprises at least 5% of the viral population;21,22 
however, it is too expensive to be adopted widely in develop-
ing countries such as China. In the present study, we estab-
lished a polymerase chain reaction-ligase detection reaction 
(PCR-LDR) assay for the simultaneous detection of the muta-
tions rtL180M, rtM204V/I, rtA181T/V, and rtN236T and the 
HBV genotypes A, B, C, and D, and evaluated its performance 
using clinical samples.
MATERIALS AND METHODS
Plasmids
The plasmids that contained the mutant and wild-type 
sequences for rt204, rt181, and rt236 were constructed pre-
viously.23,24 The plasmids that contained the mutant and 
wild-type sequences for rt180 were constructed using the 
same method described previously.24
Serum samples and extraction of HBV DNA
This study was conducted in accordance with the guidelines 
of the Declaration of Helsinki and the principles of Good 
Clinical Practice. All patients gave their informed con-
sent. Serum samples were collected from 216 patients with 
chronic hepatitis B. Of the 216 patients, 52 were treated 
with lamivudine alone, 82 were treated with adefovir alone, 
51 were treated with lamivudine initially but became re-
sistant to lamivudine and were then treated with adefovir, 19 
were treated with telbivudine, and 12 were treated with ente-
cavir. Given that drug resistance mutations often arise after one 
year of treatment, we selected patients who had been treated 
for more than 12 months but still had sufficient HBV DNA in 
their serum to be detected by real-time PCR, in order to include 
enough mutant samples to evaluate the assay. HBV DNA was 
extracted from 100 mL of serum using a QIAamp DNA Blood 
Kit (Qiagen, Chatsworth, CA) in accordance with the manufac-
turer’s instructions.
Measurement of serum HBV DNA levels
Serum levels of HBV DNA were determined by using a real-
time PCR kit (Fosun Diagnostics, Shanghai, China). The kit 
has been approved by the Chinese Food and Drug Adminis-
tration for in vitro diagnosis and has a lower limit of detec-
tion of 84 IU/mL.25 
Primers for PCR and LDR
Primers and probes (synthesized by Invitrogen, Shanghai, 
China) to detect the HBV mutations and genotypes are list-
ed in Tables 1 and 2. 
Multiplex PCR and LDR
PCR amplifications were carried out in a volume of 50 mL 
containing 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 
2 mmol/L MgCl2, 200 mmol/L dNTPs, 300 mmol/L each 
primer, 1.5 units of Gold DNA polymerase (Qiagen), and 
5 mmol/L HBV DNA template. The amplifications were per-
formed in a PE 9600 thermal cycler (Applied Biosystems, 
Foster City, CA) by heating to 95oC for 10 min, cycling 
for 35 cycles at 95oC for 30 s, 54oC for 50 s, 72oC for 60 s, 
and then performing a final extension at 72oC for 10 min. 
LDR reactions were carried out in a volume of 20 mL con-
taining 20 mmol/L Tris-HCl (pH 7.6), 10 mmol/L MgCl2, 
100 mmol/L KCl, 10 mmol/l DTT, 1 mmol/L EDTA, 
1 mmol/L NAD+, 12.5 mmol/L each probe, 3 mL of PCR 
product, and 0.1 mmol/L DNA ligase. The LDR was per-
formed in a PE 9600 thermal cycler by incubating at 95oC for 
2 min and cycling for 30 cycles at 95oC for 30 s and 
65oC for 4 min. The reaction was stopped by adding 0.5 mL 
of 0.5 mmol/L EDTA. Aliquots of 2.5 mL of the LDR prod-
ucts were mixed with an equal volume of loading buffer 
containing 80% formamide, 10 mmol/L EDTA, and 1.2% 
Blue Dextran. The mixture was denatured at 94oC for 2 min, 
chilled rapidly on ice before loading on a 10% polyacryla-
mide gel with 7 mol/L urea, and electrophoresed on an ABI 
377 DNA Sequencer (Applied Biosystems) for 30 min. The 
results were analyzed by using the GeneMapper software 
(Applied Biosystems). 
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Table 1. Primers and probes used in the PCR-LDR protocol for detection of HBV drug-resistant mutations
Primers and probes  Sequence Length of 
    product (bp)
PCR primers for 
mutation detection
 Primer 1-F 5’-CTACCAGCACGGGACCATGC-3’ 575
 Primer 2-R 5’-TACATGCATATAAAGGCATTGAGG-3’ 
LDR probes for 
mutation detection
 L180 P-GAGAAACGGACTGAGACCTACCTACCTACCTACCT-FAM 
 L180-M ACCTACCACCTACCTACCTAGTAAACTAGACCAT 70
 L180-W ACCTACCTACCTACCTACCTAAAGTAAACTGAGCCA 72
 M204-1 P-ATATAACTGAAAGCCACCTACCTACCTACCTACCTAA-FAM 
 M204-2 P-ATAACTGAAAGCCAAACCTACCTACCTACCTACCT-FAM 
 M204-W ACCTACCTACCTACCTACCTAAAATACCACATCATCC 74
 M204-I CCACCTACCTACCTACCTACCTACCTAAATACCACATCATCA 78
 M204-V ACCTACCTACCTACCTAACCTACCTATACCACATCACCCAC 80
 A181-1 P-CCAAGAGAAACGGACTGAGGCCCACTCCCATAGGAATCTTGCG-FAM 
 A181-2 P-TCAAGAGAAACGGACTGAGGCCCACTCCCATAGGAATCTTG-FAM 
 A181-M AGCCCTACGAACCACTGAACAAATGGCACTAGTAAACTGAA 84
 A181-W AAAGCCCTACGAACCACTGAACAAATGGCACTAGTAAACTGAG 86
 N236 P-TCAAATGTATACCCAAAGACAAAAGAAAATTGGTAATAGAGGTAA-FAM 
 N236-M CCATGAAGTTAAGGGAGTAGCCCCAACGTTTGGTTTTATTAGGGG 90
 N236-W TCCCATGAAGTTAAGGGAGTAGCCCCAACGTTTGGTTTTATTAGGGT 92
Table 2. Primers and probes used in the PCR-LDR protocol for HBV genotyping
Primers and probes Sequence Length of  
   product (bp)
Primers for 
HBV genotyping
 Primer-F 5’- ACTGCCTCTCCCATATCGTC-3’ 
376
 Primer-R 5’- GACAAACGGGCAACATACCT-3’ 
LDR probes for 
HBV genotyping
 Genotype B P-TCGAGGAATATGATAAAACGCCGCAGCCTACCTACCTACCTACCTACCTACCT-FAM
 108
  CCTACCTACCTACCTACTCCTACCTACCTTAAGATGAGGCATAGCAGCAGGATGT 
 Genotype C P-TACCAAGGTATGTTGCCCGTTTGTCCCACCTACC TACCTACCTAGCTACCTACCTA-FAM 110
  CCTACCTACCTACCTACCTACCTACCTGACCCTGCACCGCCAACATGGAGAAGAC 
 Genotype A P-TACCAAGGTATGTTGCCCGTTTGTCCCACCTACC TACCTACCTAGCTACCTACCTA-FAM 112
  CCTACCTACCTACCTACCTACCTACCTGACCCTTGCCTTTGTTGGTTCTTCTGGAT 
 Genotype D P-CGAAAGCCCAGGATGATGGGATGGGCCTACCTACCTACTAGTAGCCTACCTACCTACT-FAM 118
  CCTACCTACCTACCTACCTAGTAGCTACCTACCTGGGCCCACTCCCATAGGAATTTTC
PCR-LDR detecting HBV mutations and genotypes
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Sequencing and subcloning
To validate the mutation detection and HBV genotyping 
results, the 575- and 376-bp PCR products, respectively, 
were purified and sequenced by Invitrogen. Discrepancies 
between the PCR-LDR and sequencing results were resolved 
by sequencing subcloned PCR products. The PCR products 
were cloned into the pGEM-T vector (Promega, Madison, 
WI) and 20 clones for each sample were selected for se-
quencing.
RESULTS
Specificity and sensitivity
The strategy of the PCR-LDR assay has been described in 
detail previously.24 Its specificity and sensitivity were deter-
mined by using mutant and wild-type plasmids and clinical 
samples. All the plasmids produced the expected results. No 
nonspecific signals were observed at template concentra-
tions of 2 x 103, 2 x 105, or 2 x 107 copies/mL. Serum samples 
from 10 blood donors, and 20 samples from patients with 
hepatitis A and C were tested, and gave no signal. Serial dilu-
tions of the plasmids and serum samples were used to deter-
mine the lower limit of detection of the assay. Each plasmid 
was assayed three times. The PCR-LDR assay could detect 
mutant and wild-type plasmids at concentrations of 5 x 107, 
5 x 106, 5 x 105, 5 x 104, 5 x 103, and 500 copies/mL. Thus, 
the lower limit for the PCR-LDR assay was 500 copies/ml of 
mutant or wild-type plasmid. Three clinical serum samples 
with 1 x 107 IU/mL wild-type HBV, 6 x 106 IU/mL rtA181T, 
and 2 x 106 IU/mL rtN236T were serially diluted 10-fold and 
each dilution was tested in triplicate in the PCR-LDR assay. 
The PCR-LDR assay could repeatedly detect HBV in dilu-
tions containing 600 IU/mL of HBV or above, but could not 
detect HBV in dilutions containing an HBV load lower than 
600 IU/mL. Therefore, the lower limit of detection for serum 
samples was 600 IU/mL. 
Mixed plasmid experiments
Mixed plasmid experiments were performed to determine 
the ability of the PCR-LDR assay to distinguish mutant 
plasmids in a background of wild-type plasmids. 
Mutant and wild-type plasmids were mixed to give final 
total concentrations of 1 x 105 and 1 x 106 copies/mL. Each 
mixture contained 100, 10, 1, or 0.1% mutant plasmid. 
The mutant plasmids were detected in all the mixtures 
except for those that contained 0.1% mutant plasmid. 
Comparison of the LDR assay and sequencing
The PCR-LDR assay was also evaluated using serum samples 
from 216 patients who had been treated with lamivudine, 
adefovir, telbivudine, or entecavir. All samples were screened 
by both the PCR-LDR assay and sequencing. Discrepancies 
between the results obtained with the two methods were 
resolved by sequencing subcloned PCR products. The results 
of both assays are summarized in Table 3. The PCR-LDR as-
say and sequencing gave comparable results for 158 (73.1%) 
of the 216 samples with respect to mutation detection and 
genotyping. In the remaining 58 samples (26.9%), the muta-
tions and genotypes could not be detected by either method 
because insufficient product was amplified in the PCR step. 
Complete agreement between the two methods was ob-
served for all the samples (100%) at codon 180 and codon 
204. Concordant results were observed for 157 out of 158 
analyzable samples (99.4%) at codon 181 and 156 out of 
158 samples (98.7%) at codon 236. Among the discrepancies, 
PCR-LDR detected rtA181V/T and rtN236T double muta-
tions in two samples and a rtM204V and rtA181V/T double 
mutation in one sample, whereas the sequencing only de-
tected a rtA181V/T single mutation in the two samples and 
a rtM204V single mutation in the one sample, respectively. 
Table 3. Comparison of PCR-LDR and sequencing 
results
  Results of  Results of 
  PCR-LDR (n) sequencing (n)
Mutation types 
 Single rtM204I 14 (6.5%) 14 (6.5%)
 Single rtM204V 3 (1.4%) 4 (1.9%)
 Single rtA181V/T 14 (6.5%) 16 (7.4%)
 Single rtN236T 6 (2.8%) 6 (2.8%)
 rtL180M+M204I 4 (1.9%) 4 (1.9%)
 rtL180M+M204V 15 (6.9%) 15 (6.9%)
 rtM204I+rtM204V 2 (0.9%) 2 (0.9%)
 rtM204I+rtA181V/T 2 (0.9%) 1 (0.5%)
 rtM204I+rtN236T 1 (0.5%) 1 (0.5%)
 rtA181V/T+rtN236T 4 (1.9%) 2 (0.9%)
 rtL180M+rtM204V+rtA181V/T 2 (0.9%) 2 (0.9%)
 rtM204I+rtM204V+rtA181V/T 1 (0.5%) 1 (0.5%)
 Wild-type 90 (41.7%)  90 (41.7%)
 Not detected 58 (26.9%) 58 (26.9%)
 Total  216 (100%) 216 (100%)
Genotypes
 Genotype B  32 (14.8%) 32 (14.8%)
 Genotype C 116 (53.7%) 116 (53.7%)
 Genotype B+C 3 (1.4%) 3 (1.4%)
 Genotype D  7 (3.2%) 7 (3.2%)
 Not detected 58 (26.9%) 58 (26.9%)
 Total  216 (100%)  216 (100%)
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Figure 1: Some results of the PCR-LDR assay. The length of the LDR product is determined by the lengths of the LDR probes. Each 
mutant and/or wild sequences and genotypes produces a peak at the corresponding position when analyzed using GeneMapper 
software. (A) Wild-type HBV, genotype C. (B) rtM204V, genotype C. (C) rtM204I+rtA181V/T, genotype C. (D) rtM204I+rtN236T, 
genotype B. (E) rtL180M+rtM204V+ rtA181V/T, genotype C.
All the discrepancies corresponded to mutations that were 
detected by the PCR-LDR assay but not by sequencing of 
the same sample. The discrepancies were resolved by the se-
quencing of 20 randomly chosen subclones for each sample. 
In each case, at least three clones for the same sample had 
mutations that were consistent with the PCR-LDR results. 
To confirm the performance of this assay with respect to the 
detection of mutations at codons 181 and 236, we retested 
the 70 samples that had been shown to have rtA181V/T 
and/or rtN236T mutations in the previous study and 20 
samples shown to be wild type,24 and obtained consistent 
results (Figure 1). The genotyping results were completely 
concordant between the PCR-LDR assay and sequencing.
Fifty-eight samples could not be analyzed by either 
method because they could not be amplified with the PCR 
primers. Real-time PCR quantification analysis showed that 
the concentration of HBV DNA in all these samples was be-
low 600 IU/mL. 
Time required
For a panel of 64 samples, serum DNA extraction takes one 
hour. PCR-LDR takes about four hours on an ABI 9600 ther-
mal cycler. Electrophoresis takes about 1.5 hours on an ABI 
377 sequencer. The total time for the PCR-LDR assay is about 
six hours. In contrast, the sequencing analysis takes about 
13 hours, including one hour for serum DNA extraction, 2.5 
hours for PCR on a ABI 9600 thermal cycler, one hour for 
purification of PCR products, 1.5 hours for sequencing reac-
tion and purification, and seven hours for electrophoresis on 
a ABI 377 sequencer.
  70 80 90 100 110
180M 180W YMDD YIDD YVDD 181M 181W 236M 236W 184M 184W 202M 202W 250W250M CB
A
B
C
D
E
1200
1000
800
600
400
200
0
2400
2000
1600
1200
800
400
0
8000
6000
4000
2000
0
3000
2000
1000
0
1200
1000
800
600
400
200
0
PCR-LDR detecting HBV mutations and genotypes
565Braz J Infect Dis 2011; 15(6):560-566
DISCUSSION
Although HBV genotyping and the detection of drug resist-
ance mutations are important for monitoring the treatment 
of chronic hepatitis B, there are a limited number of meth-
ods for the simultaneous detection of HBV genotypes and 
mutations that confer resistance to lamivudine, adefovir, 
and telbivudine.26 We have established a PCR-LDR assay to 
detect the major HBV genotypes and the rtL180M, rtM204I, 
rtM204V, rtA181V/T, and rtN236T mutations, which are as-
sociated with lamivudine, adefovir, and telbivudine resist-
ance, in patients with chronic HBV infections. The assay 
could specifically detect mutant and wild-type HBV, and its 
lower limit of detection was 600 IU/mL for clinical serum 
samples. In a mixture of mutant and wild-type plasmids, the 
assay could detect mutant plasmids at a proportion of 1%. 
Therefore, the PCR-LDR assay was more sensitive than se-
quencing for the detection of a low level of mutant mixed 
with wild-type virus. In addition, the cost of the PCR-LDR 
assay is below 20 USD dollars per test, which is affordable 
for patients in China and other developing countries. Com-
pared to sequencing, PCR-LDR is less time-consuming. 
Fifty-eight samples could not be analyzed by either PCR-
LDR or sequencing because the level of HBV DNA in the sam-
ples was too low to be amplified in the PCR step. Although the 
clinical significance of low serum levels of HBV DNA in pa-
tients with chronic HBV infection is unclear, patients who have 
a detectable serum level of HBV DNA have a much higher risk 
of relapse after the withdrawal of antiviral agents.27 Mutations 
that occur at a low level may lead to HBV breakthrough and 
treatment failure during long-term antiviral therapy. The im-
provement of HBV DNA extraction protocols and nested PCR 
should be considered in future studies, to increase the sensitiv-
ity of detection of low levels of HBV DNA.
Theoretically, new mutations that cause resistance to 
antiviral agents used to treat HBV could be detected simul-
taneously by multiplex LDR with specific probes. We have 
designed specific probes to detect the mutations rtT184G, 
rtS202I, and rtM250V, which are associated with entecavir 
resistance. However, we did not detect these mutations in 
the clinical samples analyzed due to the low rates of these 
mutations and the relatively small number of patients 
treated with entecavir in our study. The performance of the 
PCR-LDR assay with respect to the detection of entecavir-
resistance mutations needs to be evaluated in future studies.
Although at least eight HBV genotypes have been re-
ported, the major HBV genotypes in China are B and C.28 
Genotypes A and D are found in a very small proportion 
of Chinese patients, and genotypes E, F, G, and H have not 
been reported in China. As a consequence, we could only 
evaluate the performance of the PCR-LDR assay for geno-
types A, B, C, and D, and, in fact, we did not detect genotype 
A in this study. This might be due to the very small number 
of patients infected with genotype A in eastern China.28
Separate mutations associated with lamivudine and 
adefovir resistance were detected simultaneously in sam-
ples from six patients. All these patients failed to respond 
to lamivudine treatment initially and were then treated with 
adefovir for more than 12 months. This result implies that 
sequential treatment with lamivudine and adefovir can lead 
to multi-drug resistance in HBV-infected patients, as report-
ed in other studies.29,30
In conclusion, the PCR-LDR assay developed in this study 
was able to detect HBV genotypes and the mutations associ-
ated with resistance to lamivudine, adefovir, and telbivudine 
sensitively and specifically. It might be a useful tool for decision 
making with respect to the treatment of HBV-infected patients.
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